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Background: ErbB3 expression is associated with the constitutive 
phosphorylation of epidermal growth factor receptors in non-small cell 
lung cancer (NSCLC) cell line, calu3. ErbB3 post-translational levels 
have been reported by other investigators to be regulated by Neuregu-
lin receptor dependent protein 1 (Nrdp1). Nrdp1, a ubiquitin ligase, 
down-regulates ErbB3 expression by directing it toward proteosomal 
degradation. Nrdp1 also down-regulates the expression of a large mo-
lecular weight survival protein, Bruce. The over-expression of ErbB3 in 
NSCLC then could result from loss of expression or lack of stabiliza-
tion of Nrdp1. Depressed levels of Nrdp1 expression or function could 
then lead to activation of ErbB receptor mediated signaling pathways 
and to over-expression of Bruce thereby resulting in an inhibition of 
apoptotic pathways. This combination of events could lead to con-
tinuous, uncontrolled cell proliferation. It was our goal to investigate 
the role of Nrdp1 in ErbB receptor-mediated signal transduction and 
survival pathways of NSCLC cell lines. 
Methods: Lung cancer cell lines were purchased from ATCC and 
maintained as recommended. Cells are cultured in serum-free medium 
for 24-48 hours before incubation for 1-2 hours with inhibitors of 
EGFR, inhibitors of other signal transduction pathways, or DMSO sol-
vent vehicle controls. EGF or medium is added to selected wells for the 
ﬁnal 5 minutes of culture before preparation of cell lysates for Western 
blotting. Equal protein concentrations of the lysates are applied to wells 
of PAGE-gels, then submitted to electrophoretic separation by molecu-
lar weights in SDS-Tris-glycine buffer. Signal transduction pathways 
are investigated by probing Western blots with phospho-kinase site-
speciﬁc antibodies, anti-native protein antibodies and anti-actin as 
loading control. 
Results: The calu-3 line, of seven NSCLC lines examined, revealed a 
constitutive activation of EGFR as evidence by tyr845 phosphoryla-
tion in the absence of addition of exogenous ligand. The constitutive 
phosphorylation of Tyr845 was not inhibited by the speciﬁc EGFR ty-
rosine kinase inhibitor, AG1478. Tyr845 phosphorylation was inhibited, 
however with the src-kinase inhibitor PP2, suggesting that a src-family 
associated kinase may be responsible for activating EGFR. Immuno-
precipitation studies revealed high ErbB3 expression with limiting 
levels of EGFR. ErbB2 was co-immunoprecipitated with ErbB3. Nrdp1 
expression levels were decreased in the calu-3 cell line as compared 
with another NSCLC cell line, H1975. The effect of decreased Nrdp1 
levels on expression of survival or anti-apoptotic molecules and on the 
expression of proteins that are associated with epithelial to mesenchy-
mal transition (EMT) will be reported.
Conclusions: Signaling pathways triggered through the EGFR family 
of receptors, ErbB1, B2, B3, and B4 play major roles in the devel-
opment of epithelial tumors. Constitutive activation of EGFR and 
enhanced expression of ErbB3 resulted in decreased responsiveness to 
EGFR inhibition. Inhibition of the src-kinase pathway is a viable alter-
native to inhibit signals transduced through the ErbB triggered pathway 
in these cells, and should be considered for therapy of tumors with 
similar phenotypes. The mechanisms underlying enhanced expression 
of ErbB3 may be associated with Nrdp1 levels rather than a reﬂection 
of gene ampliﬁcation. Nrdp1 levels were relatively low in the calu-3 
cell line as compared with others. Nrdp1 expression and stabilization 
may contribute to maintaining active signal transduction and the transi-
tion of epithelial cancer cells to mesenchymal type, a phenotype more 
resistant to therapy.
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Background: A new class of cancer therapeutics targeting speciﬁc 
signaling pathways activated by genetic lesions (gene mutations, gene 
copy-number changes, structural genetic changes, etc.) has shown clini-
cal success. However, the molecular heterogeneity of non-small cell 
lung cancer (NSCLC) challenges the successful clinical deployment 
of these agents. This is mostly due to the fact that only subsets of the 
tumors of a given subtype carry a speciﬁc genetic lesion (e.g., EGFR 
mutation). Such lesions cause dependency of the tumor cells on the 
activity of this oncogene and thus render the cells sensitive to agents 
targeting this oncogene or the downstream pathway. It is therefore 
desirable that the genetic lesions that lead to a particular oncogene 
dependency and thus, therapeutic vulnerability, be identiﬁed preclinical 
experiments prior to initiation of clinical trials. Likewise, taking such 
concepts into clinical testing requires real-time and accurate measure-
ment of somatic (tumor-speciﬁc) genetic lesions in the tumor, irrespec-
tive of the quality of the tumor specimen. 
Methods and Results: In order to establish a pre-clinical mechanism 
that reﬂects the genetic diversity of primary NSCLC tumors and that 
enables systematic perturbation experiments using drug cancdidates, 
we collected 84 NSCLC cell lines. We have analyzed the somatic 
genetic lesions of these cell lines by determining gene copy numbers 
using 250.000K SNP arrays, gene expression levels using exon arrays 
and mutation status of known oncogenes and tumor suppressor genes. 
Using these data the NSCLC cell lines can be characterized according 
to the pattern of genetic lesions. We also show that the genetic proﬁles 
of this cell line panel reﬂect the somatic lesion landscape of primary 
NSCLC tumors. This model system can thus be used to identify the 
genetic pattern of those cell lines that are exquisitely sensitive to a 
speciﬁc therapeutic compound. Using this system we show that cell 
lines carrying lesions in the ERBB2 gene are highly sensitive to a 
dual-speciﬁcity EGFR/Her2 kinase inhibitor. Furthermore, modelling 
sensitivity and resistance to EGFR inhibitors in the cell line collection 
recapitulates clinical observations in that cell lines carrying ampli-
ﬁed and mutated EGFR alleles were most sensitive to these inhibitors. 
These examples illustrate the power of an integrated functional genom-
ics approach to provide a preclinical rationale for the deployment of 
targeted drugs in the clinic. 
Furthermore, we have established a sensitive parallel sequencing 
method, as well as a high-throughput oncogene mutation approach for 
genetic analysis of clinical cancer specimens. These approaches will 
help translating the insights gained from preclinical screening experi-
ments into clinical practice.
Conclusions: In summary, we apply large-scale functional genomics 
approaches to generate preclinical hypotheses for the deployment of 
targeted agents in the cancer clinic. Furthermore, we are working on 
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establishing diagnostic mechanisms that enable rapid testing of these 
hypotheses in the clinic. This dual approach may provide a framework 
for a new clinical science that is driven by the knowledge of the mo-
lecular biology of individual tumors rather than by empirical determi-
nants of drug response. 
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Background: Epidermal growth factor receptor (EGFR) is a thera-
peutic target in non-small cell lung cancer (NSCLC) and head and 
neck squamous cell carcinoma (HNSCC). Patients with NSCLC with 
activating mutations in EGFR often have signiﬁcant tumor regressions 
with geﬁtinib treatment. In addition, approximately 30% of patients 
treated with geﬁtinib develop stable disease implicating additional 
mechanisms of geﬁtinib sensitivity. The majority of such patients do 
not harbor EGFR mutations and EGFR mutations in HNSCC are rare. 
As EGFR can be activated by one of its ligands (amphiregulin, EGF, 
TGF-alpha), we examined the relationship of EGFR ligands to the ef-
ﬁcacy of geﬁtinib and cetuximab using in vitro growth assays of EGFR 
wild type NSCLC and HNSCC cell lines. 
Methods: Amphiregulin, EGF and TGF-alpha in cell culture media 
was analyzed with ELISA assays in 18 cell lines, 14 NSCLC and 4 
HNSCC cell lines. This included four NSCLC with EGFR mutation. 
The remaining 14 cell lines were wild type for EGFR. All had wild type 
KRAS except for H358. The in vitro sensitivity was analyzed using 
MTS assay. EGFR, HER3, Akt, ERK1/2, Cyclin D1 and phosphoryla-
tion of these proteins were analyzed with Western blotting. Cell cycle 
was analyzed by ﬂow cytometry.
Result: TGF-alpha (range, 0 to 4.8pg/ml) was only detected in Calu3 
(116.6pg/ml) and H1666 (4.8pg/ml) cells. EGF (range, 0 to 2.2pg/ml) 
was detected at negligible level and did not vary signiﬁcantly. The pres-
ence of amphiregulin varied signiﬁcantly among the cell lines (range, 
4.6 to 1625.8pg/ml). All EGFR mutant cell lines had negligible levels 
of amphiregulin (<50.3pg/ml). Seven cell lines of the 14 cell lines 
with wild-type EGFR had > 250 pg/ml (range, 718.4 to 1625.8pg/ml) 
of amphiregulin detectable in media and all were sensitive to geﬁtinib 
with an IC50 of < 1 uM (range, 0.10 to 0.33). In addition, they were 
also sensitive to cetuximab (mean growth inhibition following10ug/ml 
cetuximab 56.8% (range, 33.1 to 87.1 %)) while those producing < 250 
pg/ml were resistant (mean growth inhibition following 10ug/ml cetux-
imab 0.95% (range -4.4 to 15.3%). Cell lines producing < 250 pg/ml 
of amphiregulin were also resistant to geﬁtinib in vitro (IC > 1 uM) In 
addition 6/7 sensitive cell lines expressed p-ERBB3 in contrast to 1/7 
resistant cell lines. The amphiregulin producing cell lines underwent 
G1/S arrest following either geﬁtinib or cetuximab treatment. Fur-
thermore, amphiregulin neutralizing antibodies inhibited growth of 3 
amphiregulin producing cell lines but not HN28, which did not produce 
amphiregulin. Amphiregulin producing sensitive cell lines exhibited 
dose dependent decrease in p-EGFR, p-ERBB3, p-Akt, p-ERK 1/2 and 
cyclin D1 following geﬁtinib. Cetuximab led to a dose dependent de-
crease in p-EGFR, p-ERK 1/2 and cyclin D1. Geﬁtinib and cetuximab 
had no effect on these proteins in cells without amphiregulin.
Conclusion: Our ﬁndings suggest that in EGFR wild type NSCLC and 
HNSCC cell lines the presence of an amphiregulin autocrine loop is a 
major determinant of in vitro sensitivity to geﬁtinib and cetuximab. In 
addition to EGFR mutations, amphiregulin expression may be suitable 
biomarker to select patients likely to beneﬁt from geﬁtinib treatment. 
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Background: Few details are known about the smoking history of 
patients developing lung cancer, especially so for users of hand rolled 
cigarettes. Norway appears to be the last Western country still using 
a signiﬁcant amount of roll tobacco, amounting to one third of total 
tobacco sales.
Methods: A prospective, questionnaire-based study on all persons de-
veloping primary lung cancer in Southern Norway between June 14th, 
2002 and June 13th, 2005.
Results: 83% of patients in an unselected population with newly 
diagnosed lung cancer had smoked primarily hand rolled cigarettes. 
The hand rolled cigarette smokers had consumed signiﬁcantly less 
pack-years of tobacco (32,3, SD19), and smoked fewer cigarettes per 
day (14,9 SD7), than those using fabricated cigarettes (40,0, SD26, 
and 19,8, SD10, p=0,023 and p<0,0001, respectively). The use of pack 
tobacco is much more frequent in this study than expected from ofﬁcial 
sales statistics. Smoking debut was 17,9 years (SD5). Mean age for 
developing lung cancer was 68 (SD11) years.
